ConductScience.org, home

Paper30034945

First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Tang X and 13 others. Am J Cancer Res, 2018. Cited by 410 papers, by iCite.

Cite this record

ConductScience Library. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Papers, record 30034945. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30034945

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
PubMed
Journal
Am J Cancer Res
PubMed
Year
2018
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
410
iCite
Relative citation ratio, by iCite
13.8
iCite
Revised in PubMed
2021-01-03
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tang XXiaowen
2Yang LLin
3Li ZZheng
4Nalin APAnsel P
5Dai HHaiping
6Xu TTing
7Yin JJia
8You FFengtao
9Zhu MMingqing
10Shen WWenhong
11Chen GGuanghua
12Zhu XXiaming
13Wu DDepei
14Yu JJianhua

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA016058NCI NIH HHSUnited StatesP30CA016058PubMed and NIHNIH RePORTER
R01 AI129582NIAID NIH HHSUnited StatesR01AI129582PubMed and NIHNIH RePORTER
R01 CA185301NCI NIH HHSUnited StatesR01CA185301PubMed and NIHNIH RePORTER
R01 NS106170NINDS NIH HHSUnited StatesR01NS106170PubMed and NIHNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in30323981Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.https://conductscience.org/library/papers/30323981

Source PubMed

Download CSV of comments and corrections

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125340009Are natural killer cells superior CAR drivers?Oncoimmunology2014https://conductscience.org/library/papers/25340009PubMed
212149207Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.Blood2002https://conductscience.org/library/papers/12149207PubMed
324596416Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.Blood2014https://conductscience.org/library/papers/24596416PubMed
424067492CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.Leukemia2014https://conductscience.org/library/papers/24067492PubMed
58152260Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.Leukemia1994https://conductscience.org/library/papers/8152260PubMed
626640245ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.J Natl Cancer Inst2016https://conductscience.org/library/papers/26640245PubMed
726155832CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.Sci Rep2015https://conductscience.org/library/papers/26155832PubMed
828496177Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.Leukemia2017https://conductscience.org/library/papers/28496177PubMed
928725044Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.Leukemia2018https://conductscience.org/library/papers/28725044PubMed
1025113226Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.Leukemia2015https://conductscience.org/library/papers/25113226PubMed
1127008316CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.J Cell Mol Med2016https://conductscience.org/library/papers/27008316PubMed
1227248327Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.Oncotarget2016https://conductscience.org/library/papers/27248327PubMed
1328838796NK cell-based immunotherapy for cancer.Semin Immunol2017https://conductscience.org/library/papers/28838796PubMed
1425373520Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.Mol Ther2015https://conductscience.org/library/papers/25373520PubMed
1527050072A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.Oncotarget2016https://conductscience.org/library/papers/27050072PubMed

Download CSV of references

Cited by337

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 410 citations.

PMIDTitleJournalYearIn PapersSource
42926223CAR-NK cell immunotherapy: a comprehensive review of engineering platforms, clinical applications in hematological and solid tumors.J Cancer Res Clin Oncol2026https://conductscience.org/library/papers/42926223PubMed
42846440Therapeutic reprogramming of natural killer cells for solid tumors: expanding frontiers into rare and ultra-rare malignancies.Front Mol Biosci2026https://conductscience.org/library/papers/42846440PubMed
42769371Harnessing Natural Killer Cells: From Neuroimmunology to Novel Therapies for Central Nervous System Diseases.MedComm (2020)2026https://conductscience.org/library/papers/42769371PubMed
42755912Progress in reprogramming failed graft-versus-leukemia immunity in acute myeloid leukemia relapse after allogeneic transplantation.Front Immunol2026https://conductscience.org/library/papers/42755912PubMed
42712866iPSC-derived CAR-NK extracellular vesicles for non-small cell lung cancer: evidence, engineering, and translational barriers.Front Immunol2026https://conductscience.org/library/papers/42712866PubMed
42665995Novel targeted therapy and cellular immunotherapy enabling allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia.Chin Med J (Engl)2026https://conductscience.org/library/papers/42665995PubMed
42662149Immunotherapy in Asia: current insights and prospects in Southeast Asia and Malaysia.Front Oncol2026https://conductscience.org/library/papers/42662149PubMed
42519392Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.Mol Ther Oncol2026https://conductscience.org/library/papers/42519392PubMed
42488645Enhancing CAR-NK persistence to unlock its full therapeutic potentials.Front Immunol2026https://conductscience.org/library/papers/42488645PubMed
42349415Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions.Cell Rep Med2026https://conductscience.org/library/papers/42349415PubMed
42316255Next-generation CAR-NK cell therapy: engineering strategies, translational challenges, and future perspectives in cancer immunotherapy.Cancer Cell Int2026https://conductscience.org/library/papers/42316255PubMed
42279415Development of Genetically Modified ARH-77 Feeder Cells for Efficient Expansion of Natural Killer Cells with Potent Anti-Tumor Activity.Cancers (Basel)2026https://conductscience.org/library/papers/42279415PubMed
42243832Exploring CAR cell therapies beyond CAR-T for myeloid malignancies.J Biomed Sci2026https://conductscience.org/library/papers/42243832PubMed
42179676Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapy.Mol Ther Adv2026https://conductscience.org/library/papers/42179676PubMed
42157284Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity.J Exp Clin Cancer Res2026https://conductscience.org/library/papers/42157284PubMed
42082268CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.J Immunother Cancer2026https://conductscience.org/library/papers/42082268PubMed
42039438CELLISA - a cell-cell binding assay for evaluation of nanovesicle targeting proteins.bioRxiv2026https://conductscience.org/library/papers/42039438PubMed
42034501Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure.Blood Rev2026https://conductscience.org/library/papers/42034501PubMed
42005464A novel cultivation strategy to recover NK cell cytotoxicity.Front Bioeng Biotechnol2026https://conductscience.org/library/papers/42005464PubMed
41969284Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy.Cancer Commun (Lond)2026https://conductscience.org/library/papers/41969284PubMed

See all 337 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD33945PubTator's text mininghttps://conductscience.org/library/genes/945NCBI Gene
CXADRP1653108PubTator's text mininghttps://conductscience.org/library/genes/653108NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30034945

GET https://conductscience.org/api/papers/v1/30034945/cited_by?page=2